#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 11 '26)

 

BMC Pediatr

1. HEIBA D, Salem N, Antonios M, Shoman W, et al
   Comparative study of post- COVID-19 Kawasaki disease and multisystem inflammatory syndrome cases at Alexandria University Children's Hospital.
   BMC Pediatr. 2026;26:644.
   PubMed         Abstract available
   
   
2. LIN C, Zhu Z, Li Y, Wei J, et al
   Diagnostic value of cytokine detection in children with Mycoplasma pneumoniae pneumonia complicated by bacterial or viral co-infections.
   BMC Pediatr. 2026;26:629.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

3. DAVOODI Z, Laurie C, Tingley K, Skidmore B, et al
   Risk-of-bias assessment of vaccine effectiveness studies: a scoping review of systematic reviews.
   Epidemiol Infect. 2026;154:e95.
   PubMed         Abstract available
   
   
4. ROSCA EC, Oke J, Jefferson T, Brassey J, et al
   Serial cycle threshold to assess the infectious potential of SARS-CoV-2: A systematic review.
   Epidemiol Infect. 2026;154:e89.
   PubMed         Abstract available
   
   

   
   J Clin Microbiol

5. MCTAGGART LR, Eshaghi A, Cronin K, Patel SN, et al
   Post-pandemic surge of Mycoplasma pneumoniae in Ontario, 2024: molecular surveillance and resistance trends relative to 2018-2023.
   J Clin Microbiol. 2026;64:e0018826.
   PubMed         Abstract available
   
   

   
   J Infect

6. LI Y, Zhang T, Gao J
   Home-Based Rapid Testing and Early Antiviral Treatment as a Potential Strategy to Blunt Pediatric Influenza Peak.
   J Infect. 2026 Jul 7:106807. doi: 10.1016/j.jinf.2026.106807.
   PubMed        
   
   

   
   J Infect Dis

7. SKELLINGTON CN, Schmidt K, Schofield C, Ganesan A, et al
   The Effect of Prevaccination Analgesics on Influenza Vaccine Immunogenicity and Effectiveness.
   J Infect Dis. 2026 Jul 10:jiag334. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

8. JIA H, Lin C, Guo Y, Cai W, et al
   A neuraminidase-targeted nanobody confers broad protection against influenza B virus.
   J Virol. 2026 Jul 10:e0076226. doi: 10.1128/jvi.00762.
   PubMed         Abstract available
   
   
9. BARRON-CASTILLO U, Berube N, Swan CL, Javed MA, et al
   Receptor profiling and growth assessment of influenza A virus in porcine mammary and non-mammary tissues and derived cells.
   J Virol. 2026 Jul 6:e0061526. doi: 10.1128/jvi.00615.
   PubMed         Abstract available
   
   

   
   MMWR Morb Mortal Wkly Rep

10. PATRICK R, Lee K, Kuan M, Chan M, et al
    Norovirus, COVID-19, and Influenza Outbreaks Among Residents and Staff Members at the Eaton Wildfire Evacuation Shelter - Pasadena, California, January-February 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:337-342.
    PubMed         Abstract available
    
    

    
    Pediatrics

11. LEONARD JS, Reinhart K, Lu PJ, Santibanez TA, et al
    Influenza Vaccine Effectiveness Against Pediatric Death in the United States: 2016-2025.
    Pediatrics. 2026 Jul 6:e2026076453. doi: 10.1542/peds.2026-076453.
    PubMed         Abstract available
    
    
12. HAHN C, Sardi A, Ratner AJ
    Averting the Unthinkable: Immunization to Prevent Childhood Deaths From Influenza.
    Pediatrics. 2026 Jul 6:e2026076867. doi: 10.1542/peds.2026-076867.
    PubMed        
    
    

    
    PLoS Comput Biol

13. WANG B, Valdano E
    Redefining and estimating the early-phase reproduction ratio for epidemic outbreaks in spatially structured populations.
    PLoS Comput Biol. 2026;22:e1014425.
    PubMed         Abstract available
    
    

    
    PLoS One

14. LI W, Tan HL, Zhuang CY, Li JY, et al
    Parental knowledge, vaccine hesitancy, and practices regarding seasonal influenza vaccination for preschool-aged children in Shenzhen, China: Insights from a cross-sectional survey.
    PLoS One. 2026;21:e0353478.
    PubMed         Abstract available
    
    
15. SANOGO IN, Puryear WB, Simulynas AF, DiGiovanni R, et al
    Serological evidence of SARS-CoV-2 exposure in marine mammals in the United States between 2020 and 2025.
    PLoS One. 2026;21:e0351734.
    PubMed         Abstract available
    
    
16. HIRATA K, Chiba T, Takaku R, Meilai C, et al
    Beyond the freedom to refuse patient: A retrospective comparative study of emergency transportation during the COVID-19 pandemic in Japan.
    PLoS One. 2026;21:e0331535.
    PubMed         Abstract available
    
    
17. HAKKI S, Nevin S, Conibear E, Madon KJ, et al
    Full blood count dynamics in immunologically naive individuals with mild COVID-19: A prospective community cohort study.
    PLoS One. 2026;21:e0353142.
    PubMed         Abstract available
    
    
18. BURCHARDI JM, Brunger M, Freitag H, Brock A, et al
    Improving the care of people affected by post-COVID syndrome (LCovB):study protocol of a mixed-methods study.
    PLoS One. 2026;21:e0353270.
    PubMed         Abstract available
    
    
19. AL-AGHBARI N
    Serum albumin and blood urea as independent predictors of in-hospital mortality in hospitalized COVID-19 patients: A retrospective cohort study.
    PLoS One. 2026;21:e0353456.
    PubMed         Abstract available
    
    
20. JEWELL M, Marye A, Barbeau B, Oakeson K, et al
    Beyond traditional outbreak investigation: Using genomic data for enhanced detection of COVID-19 disease clusters in Utah.
    PLoS One. 2026;21:e0342637.
    PubMed         Abstract available
    
    
21. IIDA K, Mori H, Remez D, Krokva D, et al
    Epidemiological characteristics of amebiasis in Japan from 2001 to 2022.
    PLoS One. 2026;21:e0318901.
    PubMed         Abstract available
    
    
22. FREDERIKSEN L, Subedi S, Choong K, Anderson J, et al
    Respiratory and bloodstream coinfections and antimicrobial use in hospitalised patients with moderate to severe COVID-19: An Australian retrospective cohort study.
    PLoS One. 2026;21:e0352344.
    PubMed         Abstract available
    
    
23. FUKUDA T, Haruyama R, Tanaka Y, Natori S, et al
    Development of a COVID-19 Vaccination Anxiety Scale to measure COVID-19 vaccine anxiety in Japanese adults.
    PLoS One. 2026;21:e0330146.
    PubMed         Abstract available
    
    
24. MICHALAKI E, Van Zanten A, Najjar J, Byagathvalli G, et al
    A piezoelectric electroporator (Piezopen) for enhanced "naked" RNA vaccine delivery.
    PLoS One. 2026;21:e0353214.
    PubMed         Abstract available
    
    
25. GACH D, van Osch FHM, van den Bergh JP, Posthuma R, et al
    Long-term multidimensional health status of individuals with and without post COVID-19 condition: A cross-sectional study.
    PLoS One. 2026;21:e0352332.
    PubMed         Abstract available
    
    
26. CONGDON C, Malik F, Jina R, Kumar D, et al
    A multi-country qualitative evaluation of rapid mortality surveillance during the COVID-19 pandemic.
    PLoS One. 2026;21:e0333157.
    PubMed         Abstract available
    
    

    
    Vaccine

27. ZHANG L, Lin T, Wang M, Ma X, et al
    Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].
    Vaccine. 2026 Jul 6:128885. doi: 10.1016/j.vaccine.2026.128885.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 5 '26)

 

Ann Intern Med

1. 
   Summary for Patients: Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed        
   
   
2. XIE Y, Choi T, Al-Aly Z
   Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   PubMed         Abstract available
   
   

   
   Antiviral Res

3. YANG X, Wu L, Wan G, Chen R, et al
   The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.
   Antiviral Res. 2026;252:106473.
   PubMed         Abstract available
   
   

   
   Arch Virol

4. ALVES MCS, Falcao RM, de Jesus Palmeira OF, de Sa Leitao Paiva-Junior S, et al
   Genomic and epidemiological characterization of SARS-CoV-2 in Northeastern Brazil: a comprehensive analysis (2020-2024).
   Arch Virol. 2025;171:1.
   PubMed         Abstract available
   
   
5. NEHUL S, Nagaraj SK, Narayan R, Singh A, et al
   A novel molecule inhibits SARS-CoV-2 RBD binding to the ACE2 receptor, blocks viral entry and exhibits antiviral activity in a murine model.
   Arch Virol. 2026;171:98.
   PubMed         Abstract available
   
   
6. MOYUE X, Liang S, Ying X, Yang Y, et al
   Research progress of nucleocapsid protein of novel coronavirus: structure, function and targeted therapy.
   Arch Virol. 2026;171:120.
   PubMed         Abstract available
   
   
7. CHEPURNOV A, Miroshnichenko S, Ivanov M, Solomatina M, et al
   Specific features of the infection caused by SARS-CoV-2 variants in Vero cell culture.
   Arch Virol. 2026;171:133.
   PubMed         Abstract available
   
   
8. JONES LR, D'Andrea JS, Levite J, Brito M, et al
   Viral genotype and the pace of epidemic waves: an assessment from SARS-CoV 2 genomics and wastewater surveillance data.
   Arch Virol. 2026;171:163.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

9. ASAFO-AGYEI SB, Ameyaw E, Nguah SB, Paintsil V, et al
   Immunisation status and clinical outcomes in children admitted to a Paediatric emergency unit in Ghana: a prospective cohort study.
   BMC Pediatr. 2025;25:981.
   PubMed         Abstract available
   
   
10. PU F, Hao YQ
    Impact of COVID-19 epidemic prevention and control measures on the incidence of asthma in children.
    BMC Pediatr. 2026;26:8.
    PubMed         Abstract available
    
    
11. AVSAR H, Bulbul A, Bas EK, Uslu HS, et al
    Maternal-infant vitamin D coupling and neonatal hypocalcemia: a six-year cohort integrating preterm risk, onset timing, and pandemic effects.
    BMC Pediatr. 2026 Jan 27. doi: 10.1186/s12887-026-06532.
    PubMed        
    
    
12. MOHAMMADI R, Barzegar H, Zamani Z, Gorji M, et al
    Hospitalization outcomes and laboratory correlations in pediatric MIS-C patients: a retrospective cross-sectional study in Tehran, Iran.
    BMC Pediatr. 2026;26:205.
    PubMed         Abstract available
    
    
13. MIYAGI Y, Morimoto Y, Satake E, Iwashima S, et al
    Identification of key clinical features for pediatric respiratory syncytial virus infection using machine learning.
    BMC Pediatr. 2026;26:266.
    PubMed         Abstract available
    
    
14. COBAN Y, Evren G, Yildizdas D, Zengin N, et al
    Burden, risk factors, and outcomes respiratory syncytial virus (RSV) infection in pediatric intensive care units in Turkiye (RSVP Study 2020-2024).
    BMC Pediatr. 2026 Mar 5. doi: 10.1186/s12887-026-06562.
    PubMed        
    
    
15. AKALIN H, Kilic A, Ozcetin M, Yildiz I, et al
    The effect of Covid 19 pandemic on childhood obesity in Turkey.
    BMC Pediatr. 2026;26:310.
    PubMed         Abstract available
    
    
16. SCHMIDT L, Feddern S, Kossow A, Niessen J, et al
    Severe acute COVID-19 and early long COVID signals in paediatric cohorts: an analysis of real-world data from two health departments, Germany.
    BMC Pediatr. 2026;26:280.
    PubMed         Abstract available
    
    
17. HANSEN G, Holt T
    RSV bronchiolitis versus COVID-19: could pediatric intensive care units have done more during the pandemic?
    BMC Pediatr. 2026 Apr 11. doi: 10.1186/s12887-026-06850.
    PubMed        
    
    

    
    J Gen Virol

18. KUOK DIT, Ma APY, Ching RHH, Ng KC, et al
    Assessment of influenza virus and coronavirus tropism, replication competence and disease severity in ex vivo and in vitro cultures of the human respiratory tract.
    J Gen Virol. 2026;107:002281.
    PubMed         Abstract available
    
    

    
    J Virol

19. LI P, Zheng Y-M, Liu S-L
    Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.
    J Virol. 2026 May 12:e0001626. doi: 10.1128/jvi.00016.
    PubMed         Abstract available
    
    
20. MCCABE M, Groves HE, Getty E, Campbell E, et al
    Age-dependent expression and antiviral activity of interferon epsilon in respiratory epithelium.
    J Virol. 2026 May 12:e0057825. doi: 10.1128/jvi.00578.
    PubMed         Abstract available
    
    
21. SIVARAJAN R, Kirchgatterer PC, Lawrenz J, Tanner-Matiz E, et al
    Tonic and early interferons defend against respiratory viruses in primary human lung organoid-derived air-liquid interface cultures.
    J Virol. 2026 May 20:e0210425. doi: 10.1128/jvi.02104.
    PubMed         Abstract available
    
    
22. FAN L, Gao X, Feng W, Huang Q, et al
    SARS-CoV-2 ORF3a suppresses host antiviral interferon responses by promoting STUB1-mediated PTEN proteasomal degradation.
    J Virol. 2026 Jun 2:e0018626. doi: 10.1128/jvi.00186.
    PubMed         Abstract available
    
    
23. SUSMA B, Spronken M, van Nieuwkoop S, Kalverda B, et al
    Increased or decreased numbers of CpG dinucleotide motifs in the genome of influenza A virus do not affect in vitro virus phenotype.
    J Virol. 2026 Jun 22:e0004726. doi: 10.1128/jvi.00047.
    PubMed         Abstract available
    
    
24. ZHANG Q, Zhang Y, Sun H, Li H, et al
    Single-cell and spatial transcriptomic profiling reveals distinct immune landscapes in murine lungs infected with H1N1 versus H5N1 influenza viruses.
    J Virol. 2026 Jun 29:e0074626. doi: 10.1128/jvi.00746.
    PubMed         Abstract available
    
    
25. KATO K, Okamura K, Nakamura Y, Iwata M, et al
    Influenza A virus infection induces initial proliferation of commensal Streptococcus pneumoniae in the larynx leading to dissemination into the lower respiratory tract.
    J Virol. 2026 Jun 29:e0055526. doi: 10.1128/jvi.00555.
    PubMed         Abstract available
    
    

    
    Pediatrics

26. GERHART J, Leister-Tebbe H, Chan PLS, McComsey GA, et al
    Nirmatrelvir/Ritonavir for the Treatment of COVID-19 in Children Aged 6 Years and Older.
    Pediatrics. 2026 Jun 25:e2025073999. doi: 10.1542/peds.2025-073999.
    PubMed         Abstract available
    
    
27. ZMUDA E, Hannon TS, Valentic J
    The Role of the Pediatrician to Promote Effective Approaches for Child and Adolescent Nutrition in Schools: Policy Statement.
    Pediatrics. 2026 Jun 15:e2026077404. doi: 10.1542/peds.2026-077404.
    PubMed         Abstract available
    
    
28. MEHROTRA-VARMA S, Nguyen HQ, Henry S, Collins J, et al
    Long-Term Outcomes of Multisystem Inflammatory Syndrome in Children up to 4.5 Years After COVID-19.
    Pediatrics. 2026;158:e2025075578.
    PubMed         Abstract available
    
    

    
    PLoS One

29. HUANG L, Wang TM, Sugimoto JD, Heberer KR, et al
    Association of SARS-CoV-2 infection with incident diabetes among U.S. Veterans in a prospective longitudinal cohort.
    PLoS One. 2026;21:e0351992.
    PubMed         Abstract available
    
    
30. ALLARDET-SERVENT J, Hezard N, Pissier C, Bardin N, et al
    Circulating biomarkers of bronchoalveolar injury help predict the need for mechanical ventilation in patients with moderate to severe COVID-19 pneumonia: A prospective cohort study.
    PLoS One. 2026;21:e0337792.
    PubMed         Abstract available
    
    
31. NAZIR A, Shorfuzzaman M, Lotfi ML, Kamalov F, et al
    Forecasting COVID-19 new cases using NBEATS deep learning and mobility data.
    PLoS One. 2026;21:e0350264.
    PubMed         Abstract available
    
    
32. WERTZ E, Babinska M, Batorski D, Louison-Lavoy D, et al
    Ad-based social media interventions increase belief accuracy and generate pro-social opinions among non-news readers.
    PLoS One. 2026;21:e0352588.
    PubMed         Abstract available
    
    
33. HERNANDEZ-ORTIZ BA, Dos Santos TA, Appolinario CM, Arcila-Cardona AM, et al
    Spatial association of seabirds and aquatic birds with highly pathogenic avian influenza (H5N1) outbreaks in Brazil: A nationwide ecological and statistical modelling approach.
    PLoS One. 2026;21:e0350505.
    PubMed         Abstract available
    
    
34. KEARNEY GD, Obi ON, Maddipati V, Levitin G, et al
    Social vulnerability and spatial patterns of COVID-19 mortality: Global implications for respiratory health equity.
    PLoS One. 2026;21:e0352270.
    PubMed         Abstract available
    
    
35. KATUSIIME L, Agbola FW
    Determinants of mobile money loan disbursements: Evidence from Uganda's post pandemic digital credit boom.
    PLoS One. 2026;21:e0338535.
    PubMed         Abstract available
    
    
36. KIERNAN EA, Guzman JD
    Paying in public: Peer effects, impression management, and willingness to pay on digital payment platforms.
    PLoS One. 2026;21:e0340550.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

37. CAO J, Liu S, Su C, Wang L, et al
    Genomic and structural evidence of SARS-CoV-2 and MERS-CoV in migratory birds.
    Proc Natl Acad Sci U S A. 2026;123:e2400023123.
    PubMed         Abstract available
    
    
38. METZGER SM, Jones TC, Meier JIJ, Richter A, et al
    Evaluation of a proposed link between the SARS-CoV-2 furin cleavage site and mouse-adapted MERS-coronavirus MA30.
    Proc Natl Acad Sci U S A. 2026;123:e2601806123.
    PubMed         Abstract available
    
    
39. TYLLIS TS, Norton TS, Abbott C, McPeake DJ, et al
    B cell-intrinsic CXCR3 drives efficient generation of ectopic pulmonary germinal center responses to influenza A virus infection.
    Proc Natl Acad Sci U S A. 2026;123:e2535787123.
    PubMed         Abstract available
    
    
40. SOEWONGSONO AC, Thompson A, Landis MJ
    Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.
    Proc Natl Acad Sci U S A. 2026;123:e2535042123.
    PubMed         Abstract available
    
    

    
    Vaccine

41. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Corrigendum to "Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial" [Vaccine 42(9) (2024) 2254-2259].
    Vaccine. 2026;88:128881.
    PubMed        
    
    
42. BARBAROUX A, Serati I, Milhabet I
    Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial.
    Vaccine. 2026;89:128894.
    PubMed         Abstract available
    
    
43. MORRIS SE, O'Halloran A, Sundaresan D, Olson SM, et al
    Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011-2020.
    Vaccine. 2026;89:128895.
    PubMed         Abstract available
    
    
44. HALWE NJ, Krammer F
    Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.
    Vaccine. 2026;89:128877.
    PubMed         Abstract available

#Pixavir Marboxil: First Approval

 

Abstract

Pixavir marboxil (Yilikang®; 壹立康®) is an oral cap-snatching endonuclease inhibitor being developed by TaiGen Biotechnology for the treatment of influenza virus infections. Pixavir marboxil recently received approval in China for the treatment of uncomplicated influenza A and B in previously healthy adults and adolescents aged ≥ 12 years. This article summarizes the milestones in the development of pixavir marboxil leading to this first approval for uncomplicated influenza A and B infections.

Source: 

Link: https://link.springer.com/article/10.1007/s40265-026-02320-2

____

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 27 '26)

 

BMC Pediatr

1. LU Q, Yu D, Liang Y, Meng Q, et al
   Antimicrobial resistance of Group A Streptococcus isolates from patients in Shenzhen, China during COVID-19 pandemic.
   BMC Pediatr. 2026 Jan 9. doi: 10.1186/s12887-025-06448.
   PubMed        
   
   
2. DOKHAN-VURAL S, Kahlert CR, Roduit C, Heldt K, et al
   Health-related quality of life, glycaemic control, lifestyle characteristics and SARS-CoV-2 prevalence in children with type 1 diabetes during the COVID-19 pandemic: results of a longitudinal, prospective single-centre Swiss study.
   BMC Pediatr. 2026 Jan 6. doi: 10.1186/s12887-025-06375.
   PubMed         Abstract available
   
   
3. TIAN L, Hu X, Qin Y, Li L, et al
   Early prediction of severe RSV-associated ALRTI in Asian pediatric patients: a simple nomogram.
   BMC Pediatr. 2025;25:968.
   PubMed         Abstract available
   
   
4. IBRAHIM HM, Kotby A, El-Ghoneimy DH, El Gendy YG, et al
   "Characteristics of children with multisystem inflammatory syndrome in children during different COVID-19 waves "Single centre Study".
   BMC Pediatr. 2025;25:988.
   PubMed         Abstract available
   
   
5. YANG M, Wang Y, Gao J, Yao C, et al
   Impact of SARS-CoV-2 variants and vaccination on pediatric febrile seizures: a retrospective cohort study.
   BMC Pediatr. 2025;25:929.
   PubMed        
   
   

   
   Cell

6. WACHARAPLUESADEE S, Saikruang W, Lytras S, Matsumoto K, et al
   Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia.
   Cell. 2026;189:4075-4093.
   PubMed         Abstract available
   
   

   
   Drugs

7. KANG C
   Pixavir Marboxil: First Approval.
   Drugs. 2026;86:1141-1145.
   PubMed         Abstract available
   
   

   
   J Virol Methods

8. IKRAR T, Muchsin W, Sophian A
   Beyond strain-specific immunity: Conserved antigenic targets, emerging platforms, and translational challenges in universal influenza and pan-coronavirus vaccine development.
   J Virol Methods. 2026;345:115432.
   PubMed         Abstract available
   
   

   
   Pediatrics

9. ARCHER HI, Watson A, Liao LD, Jacobson KB, et al
   Concordance Between Maternal and Infant COVID-19 and Influenza Vaccination Status.
   Pediatrics. 2026 Jun 24:e2025075163. doi: 10.1542/peds.2025-075163.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

10. DONG W, Yang Q, Xu L, Li X, et al
    TCRBinder: Unified pre-trained language model with paired-chain synergy for predicting T-cell receptor binding specificity.
    PLoS Comput Biol. 2026;22:e1014396.
    PubMed         Abstract available
    
    

    
    PLoS Med

11. GHISI GLM, Carson RP, Turk Adawi K, Ding R, et al
    Comparisons of core component delivery in cardiac rehabilitation programs by country income classification and decade based on the 2025 Global Audit Update: A survey study.
    PLoS Med. 2026;23:e1005151.
    PubMed         Abstract available
    
    

    
    PLoS One

12. ISHIGAKI Y, Fujita N, Kato T, Ochiai T, et al
    Airborne spread of severe acute respiratory syndrome coronavirus 2 between rooms in a sealed, mechanically ventilated ward: Evidence from a hospital outbreak investigation.
    PLoS One. 2026;21:e0350608.
    PubMed         Abstract available
    
    
13. MARTINS A, Bosco Santos MF, Nascimento J, da Silva Chui FM, et al
    Effectiveness of CoronaVac in a pioneer risk-based allocation clinical trial during the COVID-19 pandemic.
    PLoS One. 2026;21:e0351566.
    PubMed         Abstract available
    
    
14. CHEN YH, Lin CH, Liu JH, Lin HA, et al
    Effects of incentive spirometer training on dyspnea and functional status in patients with long COVID.
    PLoS One. 2026;21:e0351553.
    PubMed         Abstract available
    
    
15. BETTIO F, Tavares FF, Ticci E
    Intimate partner violence during lockdown in Tuscany, Italy: Economic or confinement-related shocks?
    PLoS One. 2026;21:e0349889.
    PubMed         Abstract available
    
    
16. CHEN X, Gao J, Qin Q, Wang C, et al
    Will there be new trends in the public's attention to express services in the post-COVID-19 era?
    PLoS One. 2026;21:e0348096.
    PubMed         Abstract available
    
    
17. CHASCIAR V, Chasciar DR, Coman C, Gherhes V, et al
    Workplace changes, perceived difficulties and migration intentions among Romanian construction workers during the covid-19 pandemic.
    PLoS One. 2026;21:e0335155.
    PubMed         Abstract available
    
    
18. KEITA NY, Onywera H, Abdou M, Dicko Z, et al
    A tale of SARS-CoV-2 genomic surveillance in Mali: Variants introductions and transmission dynamics.
    PLoS One. 2026;21:e0352020.
    PubMed         Abstract available
    
    
19. RAVINDRARAJAH R, Gittins M, Paterson L, Rogers G, et al
    Clinical and cost-effectiveness of the digital intervention, MyWay Diabetes, in people with type 2 diabetes living in Greater Manchester during the COVID-19 pandemic.
    PLoS One. 2026;21:e0349232.
    PubMed         Abstract available
    
    
20. MAJEWSKA M, Mazdziarz MA, Lepiarczyk E, Lipka A, et al
    Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma.
    PLoS One. 2026;21:e0352437.
    PubMed         Abstract available
    
    
21. YU J, Bekerian DA, Khandelwal R
    Why do people comply with health guidelines in a competing information environment?
    PLoS One. 2026;21:e0352421.
    PubMed         Abstract available
    
    
22. YUMIYA Y, Itakura M, Shiroma N, Murayama H, et al
    Factors associated with the duration of telephone observation and consultation sessions provided by the Hiroshima Prefecture Follow-up Center in the later stages of the COVID-19 pandemic in Japan.
    PLoS One. 2026;21:e0352251.
    PubMed         Abstract available
    
    
23. WILLIAMS SL, Beadle E, Williams P, Master H, et al
    A mixed-methods analysis of the implementation of a new community long-COVID service during the 2020 pandemic: Learning from practice.
    PLoS One. 2026;21:e0313367.
    PubMed         Abstract available
    
    
24. FARIS N, Hamdar L, Tamim H, Makki M, et al
    Emergency department visits and disease patterns during and after the COVID-19 lockdown.
    PLoS One. 2026;21:e0352275.
    PubMed         Abstract available
    
    
25. CHANG YS, Jones J, Hong SA, Chien LY, et al
    Factors associated with multiple births in the United Kingdom during COVID-19: A cross-sectional survey.
    PLoS One. 2026;21:e0352340.
    PubMed         Abstract available
    
    
26. BIACKOVA N, Laskov O, Adamova A, Piorecka V, et al
    Transcranial direct current stimulation in affecting neuropsychiatric symptoms of post-COVID syndrome: No change in microstates and functional connectivity.
    PLoS One. 2026;21:e0351407.
    PubMed         Abstract available
    
    
27. LAMB D, Scott H, Carr E, Stevelink SAM, et al
    Mental health of healthcare workers in England during the first three years of the COVID-19 pandemic: The NHS CHECK study cohort.
    PLoS One. 2026;21:e0350918.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. KIM T, Biswas A, Kandel S, Kuroda M, et al
    Extra gene coding capacity of SARS-CoV-2 provides a virus engineering platform for in vitro and in vivo applications.
    Proc Natl Acad Sci U S A. 2026;123:e2532920123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. MAGNUSSON AC, Lim S, Niemi C, Wolf N, et al
    Intranasal influenza vaccination using an outer membrane vesicle platform.
    Vaccine. 2026;89:128876.
    PubMed         Abstract available
    
    
30. CHEN S, Fang Y, Yu FY, Ding L, et al
    Systematic review and meta-analysis of digital seasonal influenza vaccination promotion in people aged >/=50 ?years.
    Vaccine. 2026;88:128865.
    PubMed         Abstract available
    
    
31. LEVATI E, Calvani R, Cacciatore S, Tosato M, et al
    Influenza, pneumococcal, and herpes zoster vaccination in Italy: Knowledge, uptake, and determinants across the adult life course.
    Vaccine. 2026;88:128853.
    PubMed         Abstract available
    
    
32. COUTO MONIZ M, Luo S, Krokhin A, Egorov A, et al
    Purified gamma-irradiated influenza A vaccine demonstrates high immunogenicity and protection against a drifted H1N1 strain.
    Vaccine. 2026;88:128872.
    PubMed         Abstract available
    
    
33. SHINJOH M, Furuichi M, Sugimoto R, Kawakami C, et al
    Effectiveness of inactivated and live-attenuated influenza vaccines in children during the 2025-2026 influenza season with genetically distinct influenza A and B viruses.
    Vaccine. 2026;88:128869.
    PubMed         Abstract available
    
    

    
    Virology

34. CHOWDHURY D, Vanderven HA, Wangchuk P, Sarker S, et al
    Mechanistic insights into flavonoid-mediated regulation of human influenza virus replication.
    Virology. 2026;623:111012.
    PubMed         Abstract available
    
    
35. HEREMIA L, Langsbury H, Treece J, Miller AK, et al
    Rapid GeneXpert surveillance of influenza A virus in seabirds and the environment provides early warning for wildlife health in Aotearoa New Zealand.
    Virology. 2026;623:111014.
    PubMed         Abstract available

Identification of HLA-A33-restricted #CD8+ T cell epitopes from avian #influenza #H5N1

 

Abstract

The rapid evolution of avian influenza A/H5N1, including the recent U.S. clade 2.3.4.4b outbreak, highlights its pandemic potential and the urgent need for durable, broadly protective vaccines. Given the capacity of CD8+ T cells to mediate cross-strain immunity, we investigated whether geographically distinct HLA-A33 allotypes, HLA-A*33:01 in East/Southeast Asia and HLA-A*33:03 in South Asia, differentially shape the influenza immunopeptidome and influence antiviral immunity. Antigen-presenting cells overexpressing HLA-A*33:01 or HLA-A*33:03 were transfected with single A/H5N1 antigens or infected with A/X-31 (H3N2) as a control comparison representing current seasonal influenza virus. We identified novel ligands restricted to HLA-A*33:01 (57 from A/H5N1; 55 from A/X-31) and HLA-A*33:03 (29 from A/H5N1; 45 from A/X-31). Although fewer peptides were recovered for HLA-A*33:03, a larger proportion of A/X-31-derived peptides were predicted as high-affinity binders (74%) compared with HLA-A*33:01 (61%), indicating qualitative differences in antigen presentation. To determine immunogenicity, peripheral blood lymphocytes from HLA-A*33:03-positive, A/H5N1-naïve donors were stimulated with four conserved peptides: PB2GTF, PB2KTY, NPSVQ and PB1MTK. All elicited robust CD8+ T cell activation despite the absence of prior A/H5N1 exposure, demonstrating cross-recognition by memory T cells primed against seasonal influenza. These findings define HLA-A33-restricted influenza epitopes and reveal allotype-specific presentation features that shape CD8+ T cell immunity. Conserved, immunogenic peptides identified here represent promising candidates for rational design of broadly cross-reactive vaccines to protect HLA-A33-expressing populations against severe A/H5N1 disease. Data are available via ProteomeXchange with identifier PXD078870.

Competing Interest Statement

AWP is a scientific advisor for Bioinformatics Solutions Inc (Canada), a shareholder and scientific advisor for Evaxion Biotech (Denmark), and a co-founder of Resseptor Therapeutics (Australia). These organisations had no role in the design of the study in the collection, analyses, or interpretation of data in the writing of the manuscript or in the decision to publish the results. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funder Information Declared

NHMRC, 1122099, 2016596

Source: BioRxIV, https://www.biorxiv.org/

Link: https://www.biorxiv.org/content/10.64898/2026.06.21.733083v1

____

#Antibodies against #influenza #H1N1pdm2009 and B/Victoria strains but not #H3N2 are increased in recent onset type 1 #narcolepsy versus matched controls

 

Abstract

Study Objectives: 

Onsets of Narcolepsy type-1 (NT1) increased following A/H1N1 vaccination with PandemrixTM in Europe and with A/H1N1pdm2009 infections in China and other countries. To test if other strains could trigger narcolepsy, we measured strain-specific antibodies in patients with recent onset NT1 compared to controls. 

Methods: 

Antibodies against hemagglutinin (HA) and neuraminidase (NA) were tested in 62 patients with very recent onset (onset and blood collection following a single flu season, mean +/- SEM: 0.44 +/- 0.06 years since onset) and 100 controls matched by age, sex, season and year of collection (2000-2025). Results were next extended to 181 recent onset patients (mean +/- SEM: 1.00 +/- 0.05 years) versus 260 controls, matched by sex, season and year, but having a slightly higher mean age. HA inhibition (HAI) and NA inhibition (NAI) assays were conducted using flu strains known to circulate during the corresponding flu seasons. HAI results are shown as % positive (titers >= 40) and NAI results as geometric mean titers. Odds ratio (OR) and coefficient were used to compare antibody titers in NT1 versus controls. The contribution of each assay to prediction was finally quantified in the larger sample set using Shapley decomposition. 

Results: 

NT1 patients had increased anti-HA and anti-NA antibodies against A/H1N1pdm2009 (anti-HA OR = 3.86, anti-NA coefficient = 0.35) and B/Victoria (anti-HA OR =1.90, anti-NA coefficient = 0.22), but not A/H1N1pre2009, A/H3N2, or B/Yamagata, independent of HLA-DQB1*06:02 status, age, sex, and flu season. Correlations between anti-HA and anti-NA antibodies titers were weak to moderate but significant (r2=-0.10 to 0.34). Multivariable model outperformed age-only baseline (McFadden R2 = 0.19 vs. 0.03; AUC = 0.79 vs. 0.64; likelihood-ratio test X2 = 51, p<0.001), with anti-HA against A/H1N1pdm2009 (coefficient = 0.78, p < 0.001) and anti-NA against B/Victoria (coefficient = 0.69, p < 0.001) emerging as the strongest independent predictors. 

Conclusions: 

A/H1N1pdm2009 and B/Victoria, but not other strains can trigger the autoimmune process leading to orexin cell loss in narcolepsy.

Competing Interest Statement

The authors have declared no competing interest.

Source: 

Link: https://www.medrxiv.org/content/10.64898/2026.06.13.26355596v1

____

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Jun. 20 '26)

 

Ann Intern Med

1. KOUTOURATSAS T, Dammad T, Mylonakis E
   In outpatients with COVID-19 during Omicron variant circulation, some antivirals reduce time to recovery.
   Ann Intern Med. 2026 Jun 2. doi: 10.7326/ANNALS-26-01878.
   PubMed         Abstract available
   
   
2. COTTON D
   "Never More Than 15 Feet From the Respirator": Housestaff Research During the 1955 Boston Polio Epidemic.
   Ann Intern Med. 2026 Apr 28. doi: 10.7326/ANNALS-25-05440.
   PubMed         Abstract available
   
   

   
   Arch Virol

3. AHMADY A, Mickleburgh I, Bryant N, Carnell GW, et al
   Enhanced virucidal activity of quaternary ammonium compound-thymol combinations: influence of mucin and mucoadhesive polymers.
   Arch Virol. 2026;171:215.
   PubMed         Abstract available
   
   
4. SANYAL D, Chaubey B
   SARS-CoV-2 3CL protease interaction with host factors - identifying novel drug targets.
   Arch Virol. 2026;171:202.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

5. GRUENDL M, Campos LN, Dey T, Nkurunziza T, et al
   Epidemiology of children and adolescents undergoing surgery at Mexican public hospitals: a retrospective registry-based analysis from 2010 to 2022.
   BMC Pediatr. 2026;26:553.
   PubMed         Abstract available
   
   
6. KARADENIZ HB, Zilan S, Yazici MB, Derelioglu SS, et al
   COVID-19 and first permanent molar extractions in children: a comparative retrospective study.
   BMC Pediatr. 2026;26:567.
   PubMed         Abstract available
   
   

   
   Cell

7. UEKI H, Tomita Y, Duong C, Mitake H, et al
   A CRISPR knockout mouse library for functional genomics in influenza research.
   Cell. 2026 Jun 16:S0092-8674(26)00591-X. doi: 10.1016/j.cell.2026.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

8. NEMCOVA B, Goldstein IH, Sebastian J, Minin VM, et al
   Unjustified Poisson assumptions lead to overconfident estimates of the effective reproductive number.
   Epidemiol Infect. 2026;154:e79.
   PubMed         Abstract available
   
   

   
   J Epidemiol Community Health

9. MOSCROP A, Dorling D, Cole T
   'British children are not shrinking', but child height is increasing for the wrong reasons: trends and inequalities in child measurement programme data for England, Scotland and Wales.
   J Epidemiol Community Health. 2026;80:534-540.
   PubMed         Abstract available
   
   

   
   J Gen Virol

10. NABIL NM, Tawakol MM, Hagag N, Eid S, et al
    Molecular surveillance and predictive risk modelling of avian influenza virus in wild birds in Egypt.
    J Gen Virol. 2026;107:002278.
    PubMed         Abstract available
    
    

    
    J Infect

11. LU L, Long Z, Chen F, Li Z, et al
    Global Disability-Adjusted Life Years Burden of Lower Respiratory Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae, 1990-2021: A Systematic Analysis of the Global Burden of Disease Study 2021.
    J Infect. 2026 May 25:106768. doi: 10.1016/j.jinf.2026.106768.
    PubMed         Abstract available
    
    

    
    J Infect Dis

12. NURMI V, Hedman L, Vapalahti K, Hepojoki J, et al
    Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations.
    J Infect Dis. 2026;233:e1374-e1385.
    PubMed         Abstract available
    
    
13. CASERTA MT, Mariani TJ, Walsh EE, Gill SR, et al
    Nasal Biomarkers of Acute Illness Severity and Predictors of Recurrent Wheeze in Infants Infected With Respiratory Syncytial Virus.
    J Infect Dis. 2026;233:1027-1035.
    PubMed         Abstract available
    
    
14. LIN DY, Mischell MA, Zhang X, Mollan KR, et al
    Incidence and Severity of Postacute Sequelae of SARS-CoV-2 Infection in the Omicron Era: A Prospective Cohort Study.
    J Infect Dis. 2026;233:1063-1068.
    PubMed         Abstract available
    
    

    
    J Virol

15. LV C, Wang S, Song M, Wu J, et al
    The nicotinamide phosphoribosyltransferase inhibitor FK866 restricts influenza A virus replication by perturbing viral polymerase activity.
    J Virol. 2026 Jun 15:e0059126. doi: 10.1128/jvi.00591.
    PubMed         Abstract available
    
    
16. NGUYEN X-D, Le BT, Bleich J, Espada C, et al
    Environmental temperature and relative humidity shape post-emission aerosol fate and airborne influenza transmission.
    J Virol. 2026 Jun 15:e0063426. doi: 10.1128/jvi.00634.
    PubMed         Abstract available
    
    
17. HUI X, Tian X, Xue C, Ding S, et al
    KCMF1-mediated influenza A virus PB1 ubiquitination at K653 regulates viral replication.
    J Virol. 2026 Jun 15:e0048126. doi: 10.1128/jvi.00481.
    PubMed         Abstract available
    
    

    
    Lancet

18. ABUBAKAR I, Tellez D, Aldridge RW, Altare C, et al
    The UCL-Lancet Commission on Migration and Health: review of the state of progress.
    Lancet. 2026;407:2554-2576.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

19. MCKINLEY TJ, Williamson DB, Xiong X, Salter JM, et al
    On real-time calibrated prediction for complex model-based decision support in pandemics: Part 2.
    PLoS Comput Biol. 2026;22:e1014299.
    PubMed         Abstract available
    
    
20. SHEFFIELD T, Bruneau RC, Won S, Sale KL, et al
    Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern.
    PLoS Comput Biol. 2026;22:e1014394.
    PubMed         Abstract available
    
    

    
    PLoS One

21. HIRABAYASHI K, Lorman V, Wuller S, Aragon LV, et al
    Evaluation of steroids for acute COVID in the prevention of long COVID in children: An EHR and pediatric cohort study from the RECOVER Initiative.
    PLoS One. 2026;21:e0350888.
    PubMed         Abstract available
    
    
22. ALENAZI S, Mohanty J, Srinivasan M, Samontaray DP, et al
    "The impact of COVID-19 on employee productivity and the future of remote work".
    PLoS One. 2026;21:e0351968.
    PubMed         Abstract available
    
    
23. HEUDORF U, Kowall B
    All?cause excess mortality in Germany peaked during the late?2022 influenza period, exceeding peaks during SARS?CoV?2 waves (2020-2023).
    PLoS One. 2026;21:e0335982.
    PubMed         Abstract available
    
    
24. KIM SJ, Kim J
    Symptom profiles and health-related quality of life in Korean adults with post-acute sequelae of SARS-CoV-2 infection (PASC): A latent profile analysis.
    PLoS One. 2026;21:e0351506.
    PubMed         Abstract available
    
    
25. HOLDSWORTH L, Jackson M, Piggin L, Kambulandu M, et al
    The experiences of doctors in Lesotho during the COVID-19 pandemic: A qualitative study.
    PLoS One. 2026;21:e0350935.
    PubMed         Abstract available
    
    
26. HELMSDAL G, Kristiansen MF, Gaard EK, Eysturoy BJ, et al
    Persistent symptoms, cognitive impairment, and clinical predictors of long COVID one year after Omicron infection: A clinical case-control study from the Faroe Islands.
    PLoS One. 2026;21:e0351564.
    PubMed         Abstract available
    
    
27. KEHL-FLOBERG K, Freisberg E, Pop-Vicas A, Gangnon R, et al
    Long COVID risk by pre-infection symptoms and functional status: A retrospective cohort study of data from the All of Us Research Program.
    PLoS One. 2026;21:e0330793.
    PubMed         Abstract available
    
    
28. BHAN PC, Schroeder M, Turchet D, Wen J, et al
    The time sensitivity of aspirational interventions: Evidence from a role-modeling RCT.
    PLoS One. 2026;21:e0350832.
    PubMed         Abstract available
    
    
29. WHITE DL, NonoDjotsa ABS, Ahmed ST, Boyle SH, et al
    Association between deployment and Gulf War Illness and adverse COVID outcomes in a nationwide cohort of 1990-1991 Gulf Era war veterans in the VA's Million Veteran Program.
    PLoS One. 2026;21:e0348594.
    PubMed         Abstract available
    
    
30. REID-WESTOBY C, Duku E, Gaskin A, Janus M, et al
    Chronic absenteeism in Canadian kindergarten classes, pre- and post-COVID-19, and its association with concurrent developmental vulnerability.
    PLoS One. 2026;21:e0345192.
    PubMed         Abstract available
    
    
31. YANG SD, Qi F, Colwill K, Gingras AC, et al
    SARS-CoV-2 infection in female sex workers from Nairobi, Kenya early in the COVID-19 pandemic: Seroincidence and behavioural associations.
    PLoS One. 2026;21:e0327692.
    PubMed         Abstract available
    
    
32. GEBRETEKLE GB, Lan M, Xi M, Ximenes R, et al
    Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis.
    PLoS One. 2026;21:e0351183.
    PubMed         Abstract available
    
    
33. NISSLEY-TSIOPINIS J, Fleming PF, Chan W, Langberg JM, et al
    Cluster-randomized trial of Homework, Organization, and Planning Skills program compared to treatment as usual/waitlist for youth ages 11-14: Study protocol for conceptual replication.
    PLoS One. 2026;21:e0343894.
    PubMed         Abstract available
    
    
34. EL-ATFY ES, Gadallah AM, Alsahangiti AM, Balogun OS, et al
    Laplace Transform-Based Nonparametric Test of Exponentiality against DMRL class with preservation under the Homogeneous Poisson Shock Model and applications in survival analysis and reliability.
    PLoS One. 2026;21:e0349216.
    PubMed         Abstract available
    
    
35. FATIMA Z, Surette MD, Marttala S, Leto D, et al
    Microbiome analysis of bronchoalveolar lavage (BAL) specimens from immunocompromised patients with pneumonia compared to those from healthy volunteers.
    PLoS One. 2026;21:e0351562.
    PubMed         Abstract available
    
    
36. TRAIN A, Vemuri KK, Coderre-Ball A, Silva-Valencia J, et al
    Prescription patterns of inhaler medications from 2017 to 2023: A retrospective study using Ontario administrative healthcare data.
    PLoS One. 2026;21:e0348119.
    PubMed         Abstract available
    
    
37. VASUDEV C, Mishra S, Rathi A, Fledderjohann J, et al
    Diverse coping strategies for food insecurity: A qualitative study of economically precarious households in India in the context of COVID-19.
    PLoS One. 2026;21:e0350020.
    PubMed         Abstract available
    
    
38. KHAM-KJING N, Kawila R, Tariyo P, Puapun K, et al
    Etiology of severe acute respiratory infections among adults in northern Thailand using multiplex PCR: A post-COVID-19 surveillance study (2023-2024).
    PLoS One. 2026;21:e0350198.
    PubMed         Abstract available
    
    
39. GODBOLE N, Choi S, Shim K, Liu Y, et al
    A study protocol for mixed-methods evaluation of the structure, design, and availability of medical student wellbeing programs.
    PLoS One. 2026;21:e0351759.
    PubMed         Abstract available
    
    
40. ROHAN H, Bochner AF, Brown L, Ortiz EM, et al
    COVID-19 alert level systems-Lessons learnt for future public health emergencies: A qualitative study.
    PLoS One. 2026;21:e0351209.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

41. LEVITT M, Marten B, Oren G, Ioannidis JPA, et al
    Reclassification and weighting of multiple causes of death: US death certificates 2003-2023.
    Proc Natl Acad Sci U S A. 2026;123:e2604493123.
    PubMed         Abstract available
    
    

    
    Vaccine

42. MALHOTRA G, Bilguche A, Eades O, Loftus MJ, et al
    Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study.
    Vaccine. 2026;86:128735.
    PubMed         Abstract available
    
    
43. KATANA EB, Kiiza D, Odongpiny EAL, Simbwa BN, et al
    Willingness to receive Ebola vaccines among pregnant and lactating women in Kampala, Uganda: insights from a post-outbreak cross-sectional study.
    Vaccine. 2026;86:128737.
    PubMed         Abstract available
    
    
44. GIANNINI F, Hogan AB, Blyth CC, Glass K, et al
    Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia.
    Vaccine. 2026;86:128731.
    PubMed         Abstract available
    
    
45. DVORKIN J, Pico M, Guinazu G, Crespi MS, et al
    Residual burden of severe RSV disease in infants during the first season of maternal RSVpreF immunization in Argentina: A hospital-based, multicentre, retrospective cohort study.
    Vaccine. 2026;87:128773.
    PubMed         Abstract available
    
    
46. QI X, Smolders C
    From COVAX deliveries to vaccination uptake in LMICs: a monthly panel analysis.
    Vaccine. 2026;86:128763.
    PubMed         Abstract available
    
    
47. EIDEN AL, Zheng Y, Wang D, Frew PM, et al
    Changes in attitudes and beliefs about childhood vaccination among parents in the United States: A repeat cross-sectional survey before and after the COVID-19 pandemic.
    Vaccine. 2026;87:128760.
    PubMed         Abstract available
    
    
48. DELLA CIOPPA G, Sahai N, Dodeur V, Dutton JL, et al
    Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo-
    Vaccine. 2026;87:128772.
    PubMed         Abstract available
    
    
49. MOROS A, Deulofeu M, Ribo M, Bosch-Rue E, et al
    Multiple monovalent COVID-19 PHH-1V vaccine adaptations elicit homologous and cross-neutralizing antibody responses in mice.
    Vaccine. 2026;87:128781.
    PubMed         Abstract available
    
    
50. SPILA-ALEGIANI S, Massari M, Cutillo M, Menniti-Ippolito F, et al
    Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study.
    Vaccine. 2026;88:128806.
    PubMed         Abstract available
    
    
51. BUSH C, Desai S, Wang H, Hsu WC, et al
    Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023.
    Vaccine. 2026;88:128821.
    PubMed         Abstract available
    
    
52. CHRISTOU-ERGOS M, Sabahelzain MM, Bolsewicz KT, Kaufman J, et al
    Australian adults' views on influenza vaccination: Implications for communication and service quality from a qualitative study.
    Vaccine. 2026;88:128846.
    PubMed         Abstract available
    
    
53. LE MH, Tran ND, Nguyen TTT, Phan TTN, et al
    Willingness to pay for influenza vaccination among the elderly in Vietnam: A triple-bounded dichotomous choice analysis of economic and behavioral determinants.
    Vaccine. 2026;88:128852.
    PubMed         Abstract available
    
    

    
    Virus Res

54. VALENZUELA-FUENZALIDA JJ, Velarezco LM, Silva V, Delgado F, et al
    Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Virus Res. 2026 May 20:199748. doi: 10.1016/j.virusres.2026.199748.
    PubMed         Abstract available
    
    
55. MANZOOR M, Banday MS, Para BA, Rani VI, et al
    Mental health strain due to COVID-19: Psychological distress and somatic symptoms among health care workers and the general population in Kashmir, India.
    Virus Res. 2026;369:199753.
    PubMed         Abstract available
    
    
56. TRAMONTOZZI C, Riccio A, La Frazia S, Svicher V, et al
    Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.
    Virus Res. 2026;369:199743.
    PubMed         Abstract available
    

#HK CHP continues to actively follow up on a #human case of #H9N2 virus infection and reminds public of possibility of "twin-peaks" for seasonal #influenza and #COVID19 during summer

 

    The Centre for Health Protection (CHP) of the Department of Health (DH) today (June 15) continued to actively follow up on a case of human infection with influenza A (H9) in collaboration with the relevant government departments. 

    Following whole genome sequencing and analysis of the patient's clinical specimens, the virus strain was confirmed to be a low-pathogenic avian influenza A (H9N2) virus. 

    All of the virus genes were avian in origin and no significant genetic variations were detected. 

    The patient is currently in stable condition and all six of his household contacts have remained asymptomatic. 

    As the H9N2 avian influenza virus has long been present in local poultry with low mortality rate for birds, and that the H9N2 avian influenza virus involved in this case has not shown evidence of human-to-human transmission or significant genetic variation, the CHP currently assessed the risk of a local avian influenza pandemic as low. 

    Nevertheless, the CHP once again strongly urged the public to maintain good personal and environmental hygiene at all times, avoid contact with live poultry, birds or their droppings, thoroughly cook poultry meat and eggs before consumption, and wash hands thoroughly after visiting places where live poultry is sold, so as to reduce the risk of avian influenza infection.

    In addition, with the recent rise in the activity of seasonal influenza and COVID-19, the CHP does not rule out the possibility that the activity of these two respiratory diseases will continue to rise in the coming months, leading to a "twin-peaks" phenomenon. Members of the public, particularly high-risk individuals, are advised to receive vaccination in a timely manner to reduce the risk of severe disease and death.

 

Human infection with influenza A (H9) virus

    In relation to the recent influenza A (H9) infection in a two-year-old boy, the Public Health Laboratory Services Branch of the CHP conducted whole genome sequencing and analysis of the virus, confirming that the virus strain is a low-pathogenic H9N2 avian influenza virus and that no significant genetic variations were detected. 

    The CHP has collected 17 environmental samples from the residence of the patient, the fresh provision shop at Wo Che Market he had visited, as well as a park in Fung Wo Estate. 

    One sample collected from a metal tray placed at the bottom of a live chicken cage inside the shop that was used to collect chicken droppings was tested positive for the H9 avian influenza virus. 

    The remaining 16 samples tested negative. 

    The CHP will conduct further analysis on the positive environmental sample. 

    The CHP believed that it is more likely for the boy to have contracted H9 avian influenza by touching a contaminated surface at the fresh food shop selling live poultry in Wo Che Market. Thorough disinfection and cleaning will be conducted at the fresh food shop in question.  

     The patient remains hospitalised in stable condition. His symptoms remain mild. Neither his family members nor the staff at the fresh provision shop concerned have developed any symptoms. The CHP has provided them with preventive medication and will continue to put them under medical surveillance.

     Based on the above epidemiological and virological evidence, the CHP assessed that the recent local case of infection has not changed the current risk level. The risk of an influenza pandemic due to local avian influenza remains low. The Government's response level under the "Preparedness Plan for Influenza Pandemic" remains at "Alert" level.

    Avian influenza viruses are generally classified as highly pathogenic or low pathogenic, and they mainly affect birds and poultry. Birds are also natural hosts for avian influenza viruses. 

    In occasional circumstances, cross-species transmission may occur when human come into close contact with infected poultry or contaminated environments. 

    However, there is currently no scientific evidence to suggest that the existing avian influenza viruses are capable of sustained and efficient human-to-human transmission. 

    No novel influenza virus arising from genetic reassortment between human seasonal influenza viruses and animal influenza viruses has been found either.

    Since 1999, a total of 11 cases of human influenza A (H9N2) have been recorded in Hong Kong, including five local cases and six imported cases. No fatal case has been recorded so far.

     According to data published by the World Health Organization (WHO), more than 160 cases of human infection with influenza A (H9) have been recorded globally in the past decade. The vast majority of patients presented with mild symptoms. As poultry is a natural host of the virus in many regions, sporadic human infections caused by contact with infected poultry or contaminated environments are expected to continue occurring worldwide.

     The CHP will continue to strengthen public education and publicity efforts to reduce the risk of avian influenza infection among the general public. A letter has been issued to all doctors in Hong Kong to update them on the latest situation regarding influenza A (H9), urging them to heighten vigilance and report any suspected cases.

 

Seasonal influenza and COVID-19

     Influenza activity in Hong Kong has increased in recent weeks but remains below the baseline level. 

    Based on past experience, Hong Kong may experience two influenza seasons each year. The onset of summer influenza season began at a later time than usual last year, and sustained a longer period, extending from early September last year to early January this year, resulting in the absence of the winter influenza season that traditionally occurs in the first quarter of each year. Since the summer influenza season typically occurs between July and August, it cannot be ruled out that it may begin earlier than usual this year.

     Regarding COVID-19, while overall local activity remains at a relatively low level, a slight increase has been recorded continually since early May. 

    The COVID-19 activity levels fluctuate, with an upsurge period seen approximately every six to nine months in recent years. Each upsurge is associated with changes in predominant circulating variants and a decline in community herd immunity. It has been nearly a year since the end of the last periodic upsurge of COVID-19 activity in Hong Kong, and it cannot be ruled out that the overall COVID-19 activity will rise further in the coming one to two months.

 

Government's vaccination programmes

     Vaccination remains the most effective way to prevent seasonal influenza, COVID-19 and its complications. It also reduces the risk of hospitalisation and death.

       The WHO has earlier announced its recommendations for the composition for seasonal influenza and COVID-19 vaccines in the upcoming season. Vaccine manufacturers are currently producing vaccines in accordance with the recommendations. A new batch of seasonal influenza vaccines will arrive in Hong Kong in this September, while COVID-19 vaccines will arrive in the fourth quarter.

     The COVID-19 vaccine provided under the Government's COVID-19 Vaccination Programme (the Programme) for children and adults will expire in mid-July and early September this year respectively. As the production and delivery of COVID-19 vaccines to Hong Kong with the new composition take time, eligible persons will not be able to receive free COVID-19 vaccines through the Programme for a short period during the transition period before a new batch of vaccines arrive in Hong Kong. Therefore, those in need are advised to make appointments as early as possible. Existing vaccination services will continue until the following dates:

         ° Individuals aged six months to 11 years: COVID-19 vaccination services will be available until July 10, 2026.

        ° Individuals aged 12 or above: COVID-19 vaccination services will be available until September 5, 2026.

     In addition, the shelf life of vaccines under the Government's Seasonal Influenza Vaccination (SIV) Programmes will expire at the end of July. The DH launched the 2025/26 SIV Programmes in September last year. With the government's active promotion and the cooperation of various stakeholders, over 2.03 million doses of vaccines have been administered. Members of the public who have not received vaccinations, particularly children, the elderly and chronic disease patients, should receive influenza vaccination as soon as possible.

     To prevent respiratory diseases, members of the public should maintain good personal, hand and environmental hygiene at all times. Members of the public with respiratory symptoms, even if the symptoms are mild, should wear a surgical mask, avoid crowded places and seek medical advice promptly. They should maintain hand hygiene before putting on and after removing a mask. When there is a rise in activity levels of respiratory diseases, high-risk persons should wear surgical masks when visiting public places. The general public should also wear a surgical mask when taking public transport or staying in crowded places.

     The public may visit the CHP's webpages for more information: Avian Influenza Webpage, Avian Influenza Report, COVID-19 Vaccination Programme, Seasonal Influenza Vaccination Programmes, Facebook page and Youtube channel. 

 

Ends/Monday, June 15, 2026 | Issued at HKT 22:10 | NNNN

Source: 

Link: https://www.info.gov.hk/gia/general/202606/15/P2026061500852.htm?fontSize=1

____